Detection of HBV resistance to lamivudine in patients with chronic hepatitis B using zip nucleic acid probes in Kerman, Southeast of Iran

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 8, 2012, Pages 3657-3661

  Afshar, Reza Malekpour ^a   Mollaie, Hamid Reza ^a,b  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic hepatitis B; Lamivudine; Real time PCR; Zip nucleic acids

Indexed keywords

EID: 84873677672     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.8.3657     Document Type: Article

References (22)

1. Aberle SW, Kletzmayr J, Watschinger B, et al. (2001). Comparison of sequence analysis and the inno-lipa hbv dr line probe assay for detection of lamivudine-resistant hepatitis b virus strains in patients under various clinical conditions. J Clin Microbiol, 39, 1972-4.
2. Aghasadeghi MR, Bahramali G, Sadat SM, et al. (2011). Detection of hepatitis b virus variants in hbv monoinfected and hbv/hiv coinfected iranian patients under lamivudine treatment. Curr HIV Res, 9, 263-9.
3. Amini-Bavil-Olyaee S, Hosseini SY, Sabahi F, Alavian SM (2008). Hepatitis B virus genotype and ymdd motif mutation profile among patients infected with hbv and untreated with lamivudine. Int J Infectious Diseases, 12, 83-7.
4. Arslan U, Ural O, Findik D (2008). YMDD motif variants detected by inno-lipa hbv assay in chronic hepatitis b patients during lamivudine therapy. Mikrobiyol Bul, 42, 445-50.
5. Brunelle MN, Jacquard AC, Pichoud C, et al. (2005). Susceptibility to antivirals of a human hbv strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology, 41, 1391-8.
6. Buti M, Elefsiniotis I, Esteban R (2007). Adefovir for lamivudine resistant hbv: More than meets the eye - reply. J Hepatology, 47, 619-20.
7. Chen CH, Lee CM, Tung WC, et al. (2010). Evolution of full-length hbv sequences in chronic hepatitis b patients with sequential lamivudine and adefovir dipivoxil resistance. J Hepatology, 52, 478-85.
8. Degertekin B, Hussain M, Tan J, Oberhelman K, Lok AS (2009). Sensitivity and accuracy of an updated line probe assay (hbv dr v.3) in detecting mutations associated with hepatitis b antiviral resistance. J Hepatology, 50, 42-8.
9. Elefsiniotis IS, Paparizos V, Dourakis SP, et al. (2005). Clinical outcome of long-term lamivudine treated chronic hbv infected and hiv/hbv coinfected patients. J Clinical Virology, 33, 80-2.
10. Fallahian F, Alavian S, Kayvani H, Alaeddini F, Zamani F (2010). Lamivudine resistance in iranian chronic hepatitis b patients. Shiraz E-Medical J, 11, 63-73.
11. Fasano M, Lampertico P, Marzano A, et al. (2012). HBV DNA suppression and hbsag clearance in hbeag negative chronic hepatitis b patients on lamivudine therapy for over years. J Hepatol, 56, 1254-8.
12. Geng H, Hua B, Wang H, et al. (2006). Dual-probe assay for detection of lamivudine-resistance hepatitis b virus by real-time pcr. J Virological Methods, 132, 25-31.
13. Kamar N, Sandres-Saune K, Ribes D, et al. (2004). Effects of long-term lamivudine therapy in renal-transplant patients. J Clinical Virology, 31, 298-303.
14. Li ZG, Chen LY, Huang J, et al. (2005). Quantification of the relative levels of wild-type and lamivudine-resistant mutant virus in serum of hbv-infected patients using microarray. J Viral Hepat, 12, 168-75.
15. Liu H, Mao R, Fan L, et al. (2011). Detection of lamivudine- or adefovir-resistant hepatitis b virus mutations by a liquid array. J Virological Methods, 175, 1-6.
16. Liu YC, Zhang WL, Hu Y, et al. (2010). Detection of hbv resistant mutations related to lamivudine, adefovir and entecavir by reverse hybridization technique. Cma J, 18, 414-8.
17. Moosavy SH, Froutan H, Andrabi Y, et al. (2011). Frequency of ymdd mutations in patients with chronic hepatitis b untreated with antiviral medicines. Med J Islamic Republic of Iran, 25, 186-93.
18. Noir RG, Kotera M, Pons B, Remy JS, Behr JP (2008). Oligonucleotide-oligospermine conjugates (zip nucleic acids): A convenient means of finely tuning hybridization temperatures. J Am Chem Soc, 9, 13500-5.
19. Rizzetto M, Tassopoulos NC, Goldin RD, et al. (2005). Extended lamivudine treatment in patients with hbeag-negative chronic hepatitis b. J Hepatology, 42, 173-9.
20. Voirin E, Behr JP, Kotera M (2007). Versatile synthesis of oligodeoxyribonucleotide oligospermine conjugates. Nature Protocols, 2, 1360-8.
21. Wu F, Wu MJ, Zhuge XL, Zhu SM, Zhu B (2012). Correlation of the occurrence of YMDD mutations with hbv genotypes, hbv-DNA levels, and hbeag status in chinese patients with chronic hepatitis b during lamivudine treatment. Pancreatic Diseases Int, 11, 172-6.
22. Zhou YB, Wang YF, Zhang Y, et al. (2012). In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis b virus isolates. Eur J Pharmacol, 683, 10-5.